Download Poster

Cryo-processed Leukapheresis Using Automated Closed System: A High-Quality Starting Material for Autologous and Allogeneic CAR-T Cell Therapy Manufacturing

Our latest poster, showcased at ISCT, explores how our IntegriCell™ Automated Closed Process (ACP) yields high-quality starting material suitable for both autologous and allogeneic CAR-T cell therapy manufacturing. Benefits of this automated approach include:

• Efficacy – Cryo-processing of fresh leukapheresis using an automated closed process yields high-quality material for CAR-T cell therapy.
• Cell Viability Post-Thaw – Maintains cell viability and phenotype after thawing, ensuring minimal disruption to T cell subsets and their functional characteristics.
• Comparable Performance – CAR-T cells derived from cryopreserved material demonstrate similar transduction efficiency, expansion capabilities, and cytotoxic function as those from fresh material.
• Reduced Variability – Minimizes operator-dependent variability and enhances reproducibility in the manufacturing process.
• Manufacturing Flexibility – Improved scheduling and flexibility, which is vital for the global deployment of CAR-T therapy.

Download the poster and discover how our IntegriCell™ ACP can help you enhance overall efficiency in your advanced therapy pipelines.